The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

CHICAGO (Reuters) - Repackaged injections of the cancer drug Avastin, also known as bevacizumab, have caused a cluster of serious eye infections in the Miami, Florida area, the U.S. Food and Drug ...

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...

Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases. Outlook Therapeutics has been trying to get an official approval for a reformulated ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety of off-label indications and add hundreds of millions of dollars ...

This is a preview. Log in through your library . Abstract Purpose Patients with neovascular age-related macular degeneration (nARMD) will not deteriorate on visual acuity and retinal thickness when ...

LONDON, June 11 (Reuters) - Roche's cancer drug Avastin is a cheap, effective treatment for preventing blindness and should be used routinely in countries that cannot afford the far more costly ...

One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...

The widely used cancer drug Avastin could save the eyesight of tens of thousands of people with age-related macular degeneration of the wet form, British researchers said Friday. The drug provides an ...

The FDA has issued an alert that repackaged intravitreal injections of the drug Avastin have caused at least a dozen serious eye infections in the Miami area, according to an FDA news release. The ...